ArticleJournal for immunotherapy of cancer2019
Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Delayed vaccine-induced CD8Journal for immunotherapy of cancer · 2023Article
- Review
- Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.MedComm · 2023Review
- Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.JCI insight · 2023Article
- 'Stem-like' precursors are the fount to sustain persistent CD8Nature immunology · 2022Review
- CD8Frontiers in immunology · 2022Review
- Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients.Current oncology (Toronto, Ont.) · 2021Article
- CD8 T Cell Vaccines and a Cytomegalovirus-Based Vector Approach.Life (Basel, Switzerland) · 2021Review
- Optimal CD8Immunology · 2021Article
- Influenza- and MCMV-induced memory CD8 T cells control respiratory vaccinia virus infection despite residence in distinct anatomical niches.Mucosal immunology · 2021Article
- Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer.Journal for immunotherapy of cancer · 2020Article
- STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Tcf1Nature communications · 2020Article
- Vaccine Vectors Harnessing the Power of Cytomegaloviruses.Vaccines · 2019Review
- Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.Journal of virology · 2019Article
- Fuel and brake of memory T cell inflation.Medical microbiology and immunology · 2019Review
- The hallmarks of CMV-specific CD8 T-cell differentiation.Medical microbiology and immunology · 2019Review
- Vaccine vectors: the bright side of cytomegalovirus.Medical microbiology and immunology · 2019Review
- Persistent viral replication and the development of T-cell responses after intranasal infection by MCMV.Medical microbiology and immunology · 2019Article
- From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer.Vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer vaccine platform. Defined immune thresholds for tumor protection and the factors affecting such thresholds have not well been investigated in cancer immunotherapy. We here determined using CMV as a vaccine platform whether critical thresholds of vaccine-specific T cell responses can be established that relate to tumor protection, and which factors control such thresholds.
methodsWe generated CMV-based vaccine vectors expressing the E7 epitope and tested these in preclinical models of HPV16-induced cancer. Vaccination was applied via different doses and routes (intraperitoneal (IP), subcutaneous (SC) and intranasal (IN)). The magnitude, kinetics and phenotype of the circulating tumor-specific CD8
resultsImmunization with CMV-based vaccines via the IP or SC route eliciting vaccine-induced CD8
conclusionsThis study highlight the effectiveness of CMV-based vaccine vectors, and shows that demarcated thresholds of vaccine-specific T cells could be defined that correlate to tumor protection. Together, these results may hold importance for cancer vaccine development to achieve high efficacy in vaccine recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.